| 前收市價 | 3.1500 |
| 開市 | 3.2100 |
| 買盤 | 3.6500 |
| 賣出價 | 3.7500 |
| 拍板 | 115.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 3.2100 - 3.8000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 3.37千 |
ZacksExelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
Insider Monkeyerck & Co. (MRK): Winrevair Approval Drives Cardiovascular Growth
We recently published a list of 7 Most Profitable Cheap Stocks To Invest In. In this article, we are going to take a look at where Merck & Co. (NYSE:MRK) stands against the other most profitable cheap stocks to invest in. Insights on Small Caps, Tech, and More Sherry Paul, Morgan Stanley Private Wealth Management […]
- Insider Monkey
Is Merck & Co. Inc. (MRK) The Most Undervalued Quality Stock To Buy According To Analysts?
We recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will look at where Merck & Co. Inc. (NYSE:MRK) ranks among the most undervalued quality stocks to buy according to analysts. Are More Rate Cuts Necessary to Maintain The Current Economic Trajectory? Despite global […]
